Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Blood Cancer Journal|May 26, 2023
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcomeJulia-Annabell Georgi, Sebastian Stasik, Jan-Niklas Eckardt, et al.
Blood Cancer Journal|January 24, 2023
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcomeJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Haematologica|April 24, 2024
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimensDavid Baden, Sven Zukunft, Gema Hernandez, et al.
Leukemia|October 13, 2023
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Annals of Hematology|July 8, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AMLLydia Kretschmer, Leo Ruhnke, Christoph Schliemann, et al.
Blood Advances|August 19, 2025
International Consensus Guidelines for the Conduct and Reporting of CAR T-Cell Clinical Trials in AMLSwati Naik, Richard Aplenc, Susanne H C Baumeister, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.
American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.
Blood Cancer Journal|October 5, 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.
Blood Advances|November 6, 2024
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemiaLeo Ruhnke, Marius Bill, Sven Zukunft, et al.
Pageof 8